SavedAdd your journal

Journals / Journal of critical and intensive care (Online) / 2020 / Cilt: 11 - Sayı: 1

Treatment of the Cytokine Storm in COVID-19

Arzu TOPELİ
Burçin HALAÇLI
Pages
36–40
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hereby, we tried to emphasize someanti-cytokine drug and treatment modalities for COVID-19 patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cytokine storm has been proposed as the basis of the pathophysiological process of COVID-19 causedby SARS-CoV-2.
📊
Key Findings & Data:For this reason, manytreatment options that have been tried before have been applied for COVID-19 patients as well.
💡
Conclusion & Impact:Hereby, we tried to emphasize someanti-cytokine drug and treatment modalities for COVID-19 patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cytokine storm has been proposed as the basis of the pathophysiological process of COVID-19 causedby SARS-CoV-2. Cytokine storm, generally known as excessive or uncontrolled release of especially proinflammatory cytokines, occurs due to several infectious and non-infectious causes. For this reason, manytreatment options that have been tried before have been applied for COVID-19 patients as well. Althoughthere is not a proven treatment so far, there are some promising agents. Hereby, we tried to emphasize someanti-cytokine drug and treatment modalities for COVID-19 patients.

🔖

Cite This Article

TOPELİ, A., HALAÇLI, B. (2022). Treatment of the Cytokine Storm in COVID-19. Journal of critical and intensive care (Online), Cilt: 11 - Sayı: 1, 36–40. https://ajindex.com/articles/562308

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497‐506
  2. Halacli B, Kaya A, Topeli A. Critically-ill COVID-19 patient. Turk J Med Sci. 2020; 50 (SI-1): 585‐91
  3. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395 (10229): 1033‐34
  4. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017; 39 (5): 517‐28
  5. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24 (6): 739‐48
  6. Chen L, Liu HG, Liu W, et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua jie he he hu xi za zhi = Zhonghua Jiehe he Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases. 2020 Feb; 43 (0): E005
  7. Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia [published online ahead of print, 2020 Apr 25]. Cytokine Growth Factor Rev. 2020; S1359-6101 (20) 30048-4
  8. La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019; 133 (23): 2465‐77
  9. Halacli B, Unver N, Halacli SO, et al. Investigation of hemophagocytic lymphohistiocytosis in severe sepsis patients. J Crit Care. 2016; 35: 185‐90
  10. Henter JI, Horne A, Arico ́ M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007; 48 (2): 124-31 11. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the H Score, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014; 66 (9): 2613–20
  11. Alijotas-Reig J, Esteve-Valverde E, Belizna C, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the antiviral therapy: A comprehensive review. Autoimmun Rev. 2020; 102569
  12. Henderson LA, Canna SW, Schulert GS, et al. On the Alert for Cytokine Storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020; 10.1002/art.41285
  13. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020; 214: 108393
  14. Ye Q, Wang B,